Abstract 4395
Background
In BMA117159, GSK2857916, a humanised (IgG1), afucosylated, anti-BCMA monoclonal antibody conjugated to monomethyl auristatin-F, has shown clinical activity (overall response rate [ORR]=60%; mPFS 12 months [95% CI, 3.1–NE]) as monotherapy in heavily pre-treated patients with MM. Pre-clinical data indicate that GSK’916 induces immunogenic cell death that activates dendritic cells and an antigen-specific T-cell response. PD-L1 overexpression may be a mechanism of immune evasion in MM. Pembrolizumab, a selective, humanised IgG4 anti-PD-1 monoclonal antibody that blocks the interaction of PD-1 with PD-L1 and PD-L2, may synergise with immunomodulatory drugs to enhance tumor suppression. T-cell-dependent antitumor response induced by GSK’916 may be augmented by combining with pembrolizumab.
Trial design
DREAMM 4 is a Phase I/II, single-arm, open-label, two-part study to evaluate safety and determine the recommended Phase 2 dose (RP2D) and clinical activity of GSK’916 in combination with pembrolizumab in patients with RRMM previously treated with ≥3 prior lines. Part 1 (dose escalation) will evaluate two doses of GSK’916 with a fixed dose of pembrolizumab in up to 12 participants. Modified Toxicity Probability Interval design will guide GSK’916 dose escalation. Primary objectives of Part 1 are to define safety and tolerability and define the RP2D dose of GSK’916 combined with pembrolizumab. Part 2 (dose expansion) will evaluate clinical activity of the RP2D, confirm safety, and collect pharmacokinetic information for GSK’916 in up to 28 participants. Dose expansion may stop early for futility at interim analysis. An additional stopping rule may stop enrolment early if the observed rate of treatment-related ≥Grade 4 AEs equals or exceeds the specified rate (12%). Part 2 objectives are to assess the ORR and confirm the safety profile of GSK’916 and pembrolizumab. Patients will continue combination treatment for 35 cycles or until progression, intolerance, consent withdrawal or death. Enrolment began in March 2019 and is ongoing.
Clinical trial identification
NCT03848845 (Rel. 19Feb2019).
Editorial acknowledgement
Clare Slater, PhD, of Fishawack Indicia Ltd, UK, funded by GlaxoSmithKline (GSK).
Legal entity responsible for the study
GlaxoSmithKline.
Funding
GlaxoSmithKline and is in collaboration with Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; drug linker technology licensed from Seattle Genetics; monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa.
Disclosure
S. Trudel: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: GlaxoSmithKline. A. Nooka: Honoraria (self), Advisory / Consultancy: Emory University Winship Cancer Institute; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Takeda; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Janssen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Celgene; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): GlaxoSmithKline; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Amgen; Honoraria (self), Advisory / Consultancy: Adaptive; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Spectrum; Research grant / Funding (institution): Aduro; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): KITE pharmaceuticals. D. Fecteau: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxoSmithKline. M. Talekar: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxoSmithKline. R.C. Jewell: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxoSmithKline. D. Williams: Full / Part-time employment: GlaxoSmithKline. J. Evans: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxoSmithKline. J. Opalinska: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxoSmithKline.
Resources from the same session
5107 - Tolerability of PCV in Low Grade Glioma: a Real World Experience
Presenter: Razia Aslam
Session: Poster Display session 1
Resources:
Abstract
6171 - Molecular EGFR/PD-L1 profile of glioblastoma: Hints for therapeutic strategies
Presenter: Wojciech Szopa
Session: Poster Display session 1
Resources:
Abstract
4418 - Role of Intraoperative MRI (iMRI) in neurosurgery, potential imaging tool for maximizing gross total resection (GTR) rate of CNS tumours.
Presenter: Shweta Wadhwa
Session: Poster Display session 1
Resources:
Abstract
4791 - Tumor related impairments of neurocognitive functions in patients with brain metastases
Presenter: Lei Wen
Session: Poster Display session 1
Resources:
Abstract
5372 - Is radiation therapy influencing Alzheimer’s in Brain and Head and Neck Cancers?
Presenter: Anas Saad
Session: Poster Display session 1
Resources:
Abstract
2329 - Mature Treatment Results of 120 Cases of Acoustic Neuroma Treated with Cyberknife at a single institution.
Presenter: Shawn Malone
Session: Poster Display session 1
Resources:
Abstract
3207 - A phase II/III trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma: the STELLAR study
Presenter: Cyrillo Brahm
Session: Poster Display session 1
Resources:
Abstract
3589 - CNS penetration and Preliminary Efficacy of Sacutizumab Govitecan in Breast Brain Metastasis and Glioblastoma: A Surgical Study
Presenter: Andrew Brenner
Session: Poster Display session 1
Resources:
Abstract
1969 - Wedge resection with omission of lymph node dissection as an optional treatment strategy in octogenarians or older with early stage non-small cell lung cancers
Presenter: Takahiro Mimae
Session: Poster Display session 1
Resources:
Abstract
5116 - Characterization of lung tumorspheres reveals cancer stem-like cells potential targets and prognostic markers in non-small cell lung cancer
Presenter: Alejandro Herreros Pomares
Session: Poster Display session 1
Resources:
Abstract